Compare PHI & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHI | ITGR |
|---|---|---|
| Founded | 1928 | 1970 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 2.4B |
| IPO Year | 1953 | 2000 |
| Metric | PHI | ITGR |
|---|---|---|
| Price | $21.68 | $72.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $93.71 |
| AVG Volume (30 Days) | 65.7K | ★ 574.4K |
| Earning Date | 11-11-2025 | 10-23-2025 |
| Dividend Yield | ★ 5.54% | N/A |
| EPS Growth | ★ 9.36 | N/A |
| EPS | 2.32 | ★ 2.42 |
| Revenue | ★ $3,761,997,877.00 | $1,831,074,000.00 |
| Revenue This Year | $2.70 | $9.58 |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | ★ $9.36 | $29.95 |
| Revenue Growth | 1.69 | ★ 9.54 |
| 52 Week Low | $18.61 | $62.00 |
| 52 Week High | $25.12 | $146.36 |
| Indicator | PHI | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 50.43 |
| Support Level | $21.51 | $69.12 |
| Resistance Level | $22.20 | $73.49 |
| Average True Range (ATR) | 0.32 | 1.61 |
| MACD | -0.13 | 1.06 |
| Stochastic Oscillator | 22.22 | 85.81 |
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.